FINWIRES · TerminalLIVE
FINWIRES

Neo Performance Materials Commissions Heavy Rare Earth Separation Production Line In Europe

-- Neo Performance Materials (NEO.TO) said Friday that it has commissioned its heavy rare earth element (HREE) solvent extraction small-scale production line at its Silmet facility in Estonia.

The line is operating at nameplate capacity, and efforts are now focused on delivering stable product purity before transitioning to routine production capacity, a statement said.

The operation has produced its first separated terbium and dysprosium process solutions, required for metal making, from mixed rare earth carbonate feedstock, with all processing completed in Europe, a significant a milestone, Neo said.

"The successful launch of our heavy rare earth separation in Estonia represents a critical step in Neo's strategy to build the most vertically integrated rare earth magnetics value chain in Europe," said chief executive Rahim Suleman.

"Our rare earth value chain now spans both light and heavy rare earth processing, enabling the separation and finishing of select elements into value-added, engineered end-use applications. This achievement enables Neo to provide secure, traceable, and high-quality heavy rare earth materials to our European permanent magnet facility, supporting our customers' most demanding applications."

Neo's heavy rare earth separation initiative complements its European permanent magnet facility in Estonia, which is advancing through customer qualification milestones, with commercial production expected to ramp later in 2026.

Neo shares closed up $0.76, to $22.60 on Thursday, on the Toronto Stock Exchange.

Related Articles

Sectors

Sector Update: Financial Stocks Retreat Late Afternoon

Financial stocks were declining in late Tuesday afternoon trading, with the NYSE Financial Index decreasing 0.6% and the State Street Financial Select Sector SPDR ETF (XLF) off by 0.3%.The Philadelphia Housing Index was adding 0.8%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) fell 1.6%.Bitcoin (BTC-USD) was decreasing 0.2% to $75,717, and the yield for 10-year US Treasuries rose 4.2 basis points to 4.29%.In economic news, US retail sales rose 1.7% in March, above the 1.4% increase expected in a Bloomberg-compiled survey and following the previous month's revised 0.7% gain. Removing both motor vehicles and a 15.5% surge in gasoline station sales, retail sales were up 0.6% in March, the same as in February.US pending home sales increased more than expected in March despite higher mortgage rates, data from the National Association of Realtors showed.In corporate news, JPMorgan Chase (JPM) is working to secure approval from securities regulators in China to launch actively managed exchange-traded funds in the country for the first time, Bloomberg reported. JPMorgan shares were down 1.3%.Coinbase (COIN) and Gemini Titan have been sued by New York Attorney General Letitia James for allegedly violating the state laws against illegal gambling with their prediction markets, Reuters reported, citing complaints filed in a state court in Manhattan. Coinbase shares fell past 7%.Washington Trust Bancorp (WASH) reported late Monday a year-over-year decline in Q1 revenue that also trailed analysts' estimates. Its shares tumbled nearly 17%.Barclays (BCS) is facing scrutiny from UK regulators over its use of significant risk transfer, or SRT, transactions, Bloomberg reported. The review, known as a Section 166 probe, has been requested by the Prudential Regulation Authority, the supervisory arm of the Bank of England, the report said. Barclays shares fell 2.9%.

$BCS$COIN$JPM$WASH
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) decreased 1%.In corporate news, Passage Bio (PASG) faces a tougher path after US regulators told the company it will need to run a randomized study to support approval of its experimental treatment PBFT02, a move that adds time, cost, and uncertainty, Wedbush said Tuesday in a report. Wedbush downgraded Passage Bio's stock to neutral from outperform and cut its price target to $8 from $32. Passage Bio shares dropped 2.9%.Merck (MRK) and Japanese health care company Eisai said Tuesday that phase 3 trials of two drug combinations failed to meet primary endpoints of progression-free survival and overall survival as a first-line treatment of patients with advanced clear cell renal cell carcinoma compared with Keytruda plus Lenvima. Merck shares fell 3.7%.UnitedHealth Group (UNH) raised its full-year earnings outlook on Tuesday as the health insurance giant recorded an unexpected annual increase in its first-quarter results. Its shares jumped past 7%.Quest Diagnostics (DGX) shares popped more than 4% after it reported higher Q1 adjusted earnings and net revenue and raised its 2026 outlook.

$DGX$MRK$PASG$UNH
Sectors

Sector Update: Tech Stocks Higher Late Afternoon

Tech stocks advanced late Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (XLK) increasing 0.7% and the State Street SPDR S&P Semiconductor ETF (XSD) gaining 2.6%.The Philadelphia Semiconductor index rose 1.1%.In corporate news, Amazon.com-backed (AMZN) Anthropic could reach an agreement to deploy its AI models for use by the US Department of Defense, CNBC reported, citing an interview with President Donald Trump. Amazon shares rose 0.6%.Apple (AAPL) said that Tim Cook will step down as chief executive of the iPhone maker and become executive chairman, with hardware engineering veteran John Ternus set to succeed him as CEO. Apple shares were down 2.4%.Moody's (MCO) said Tuesday that it is deepening its partnership with Microsoft (MSFT) by embedding its credit intelligence into Microsoft 365 Copilot and other AI-driven enterprise tools, expanding its presence across financial workflows. Microsoft shares gained 1.5%.Intel (INTC) is expected to report a "slight beat" in its fiscal Q1 results amid robust server CPU demand, RBC Capital Markets said in a note. Intel shares rose 0.2%.

$AAPL$AMZN$INTC$MSFT